诺和诺德是一家致力于人类健康事业、拥有众多生物技术人才的制药公司。在研发方面，我们在 80 多年的时间里始终保持着全球糖尿病研究的领先地位。我们在研究与开发领域的生物技术专家创造了诺和诺德在生物制药方面的众多成果，其中包括：人胰岛素，速效胰岛素制剂，长效胰岛素类似物，生长激素，基因重组凝血因子 VIIa 和胰高血糖素等。

我们充分掌握了基于细菌，酵母和哺乳动物细胞的蛋白质表达，也同样在蛋白质药物给药系统方面处于前沿地位。在上述糖尿病，蛋白质给药系统研究三方面的优势，构成了我们研发的战略核心，其目的不仅是要在糖尿病治疗领域处于领先地位，而且也要利用我们的生物技术平台，在新出现的治疗领域占据领先地位。

在新的千年中，要在糖尿病及生物技术研究方面取得成功，很大程度上依赖于研发组织迅速调整及适应变化的能力和意愿以及相应的全球网络。我们对自己研发组织的调整适应能力充满信心，因为我们的组织倡导机会均等的理念，在这样的机构中，令人向往的职业发展机会不仅存在于各研发分支和管理组织中，而且也存在于特别的专项研究、项目及科学的资产管理业务中。

诺和诺德公司在研发方面的年投入超过 5 亿欧元，这使我们能够获得多种技术支持，保证科学研究具备高效率、高质量、和高竞争力。在全球，诺和诺德从事研发活动的人员超过 3000 名，占到员工总数的 19% ，涉及的领域多种多样，其中包括：基础研究与发现、临床前及临床开发、生产 / 配方和给药系统、法规、质量、许可申请、专利申请、产品类管理、生物伦理和其它。

诺和诺德公司将继续致力于在所有上述领域吸引和保持优秀的人才。我们相信我们是同行业中的佼佼者，而且这一地位为我们在研发方面辉煌的昨天、今天和充满希望的明天奠定了基础。未来仍充满挑战，但我们坚信我们会一直保持成功，因为我们有基于核心优势的研发战略，以及引以自豪的工作方式。

Novo Nordisk Global R&D

Novo Nordisk is a focused healthcare company with biotechnological expertise. In terms of R&D, the strong focus is reflected by the worldwide leadership position that we have maintained within the area of diabetes research for more than 8 decades. Likewise, the biotech expertise that characterizes both our research and development units is evidenced by the many biopharmaceuticals that have been discovered and developed by Novo Nordisk: human insulin, insulin aspart, insulin detemir, growth hormone, FVIIa and glucagons.

Our ability to master protein expression in bacteria, yeast and mammalian cells is complemented by similar cutting edge capabilities within protein drug deliver. The above three sets of competences-research into diabetes, proteins and the delivery of these -form the basis for our R&D strategy which aims at providing diabetes care leadership and furthermore, at making a difference in other areas of unmet therapeutic need where we can fulfil these competitively by use of our biotechnological platform.

Success within diabetes and biopharmaceutical research in this millennium depends heavily on the ability and willingness of the R&D organization to adapt to change swiftly and moreover, to work through international networks. We have the ambition of ensuring adaptability of our research organization by having a flat organizational structure in which exciting career opportunities exist not only within the various R&D disciplines and the management of these, but also within a specialist track and finally, project and scientific asset management.

Novo Nordisk continues to have focus on being able to attract and maintain the most qualified people that are available in all of these areas. We believe that we are the preferred employer in our field of activity and that this position has paved the road for the historic and present success of innovations deriving from our R&D. The future will be challenging but it holds the promise of continued success, driven by an R&D strategy that is based on our core competencies, and a way of working that we can all take part in with pride.